|
| Day 1: Thursday, 28 January 2010 |
| |
|
| 08:50 |
Opening Remarks by Chair: Dr. Mohammad Mohamadiyeh, MD, MSc, FEBNM, Chief & Senior Consultant, Nuclear Medicine, Tawam Hospital/Johns Hopkins, Al Ain, UAE |
| |
|
| Session 1: PET/CT |
| |
|
| 09:00 |
Quantitative Imaging of Treatment Response with PET in Breast and other Cancers
Dr. Richard Wahl, Director; Nuclear Medicine/PET; Vice Chair, New Technology and Business Development, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA |
| |
|
| 09:20 |
Diagnosis and Treatment of Neuroendocrine Tumours
Prof. Sobhan Vinjamuri, MD, MSc, FRCP, Consultant, Nuclear Medicine, Royal Liverpool University Hospital, UK |
| |
|
| 09:40 |
Use of PET/CT in Lung Cancer and Identifying Nodal Stations: Clarification of the New 7th Revision of Nodal TNM Classification
Dr Rakesh Ganatra, Consultant Radiologist, Nuclear Medicine Physician and PET/CT Specialist, Nottingham University Hospitals, UK |
| |
|
| 10:00 |
CT Component of 18FDG PET/CT: Technical Considerations, Protocols and Diagnostic Value
Dr. Mohei Abu Zeid, Consultant Nuclear Medicine, Department of Radiology, King Faisal Specialist Hospital and Research Center Riyadh, KSA |
| |
|
| 10:20 |
Q & A |
| |
|
| 10:30 |
Refreshment Break |
| |
|
| Session 2: Radiation Oncology/Planning |
| |
|
| 11:00 |
Introduction to the PERCIST Criteria for Quantitative PET Treatment Response Assessment
Dr. Richard Wahl, Director; Nuclear Medicine/PET; Vice Chair, New Technology and Business Development, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA |
| |
|
| 11:20 |
PET/CT in RTP – Why? How? When?
• Anatometabolic imaging through PET/CT
• Optimized PET/CT imaging: disease specific imaging protocols
• Concept of image-guided RTP
• PET/CT-based RTP:
o Diagnosis/staging
o Definition and delineation of active tumour volume
o Restaging
o Follow-up
Priv.-Doz. Dr. Lutz S. Freudenbery, MA, MBA, Senior Physician, Zentrum for Radiology and Nuclear Medicine; Research Fellow, Department of Nuclear Medicine, University of Duisburg-Essen, Greven-broich, Germany |
| |
|
| 11:40 |
Molecular Imaging in Cancer Management: Experience of the First PET/CT in the UAE
Dr. Aly Abdel Razek, MD, FACRO, Executive Director, Gulf International Cancer Centre, Chief of Radiation Oncology, Abu Dhabi, UAE |
| |
|
| 12:00 |
New Modalities in Radiation Oncology
Dr. Maryam Aslani, MD, FRCPC, FACRO, Consultant Radiation Oncologist, Gulf International Cancer Center, Abu Dhabi, UAE |
| |
|
| 12:20 |
Q & A |
| |
|
| 12:30 |
Lunch |
| |
|
| Session 3: Paediatric Oncology |
| |
|
| 14:00 |
Clinical PET/CT: How Much Dose is Needed?
• Different PET/CT imaging scenarios and protocols and associated exposure levels for staff and patients
• Options for dose reduction through CT protocol optimization and new PET imaging technology
Priv.-Doz. Dr. Lutz S. Freudenbery, MA, MBA, Senior Physician, Zentrum for Radiology and Nuclear Medicine; Research Fellow, Department of Nuclear Medicine, University of Duisburg-Essen, Greven-broich, Germany |
| |
|
| 14:30 |
Treatment of Paediatric Tumours
Speaker TBA |
| |
|
| 15:00 |
Late Effects of Cancer Therapies
Speaker TBA |
| |
|
| 15:30 |
Refreshment Break |
| |
|
| Session 4: Nuclear Medicine |
| |
|
| 16:00 |
SPECT-CT in Clinical Practice
Dr. Richard Wahl, Director; Nuclear Medicine/PET; Vice Chair, New Technology and Business Development, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA |
| |
|
| 16:20 |
Radioimmunotherapy in Clinical Practice
Prof. Sobhan Vinjamuri, MD, MSc, FRCP, Consultant, Nuclear Medicine, Royal Liverpool University Hospital, UK |
| |
|
| 16:40 |
Investigation of Suspected Pulmonary Embolism - Which is best, V/Q or CTPA?
Dr. Rakesh Ganatra, Consultant Radiologist/Nuclear Medicine Physician, Queens Medical Centre, Nottingham, UK |
| |
|
| 17:00 |
Radionuclide Therapy
Dr. Abdulaziz Al Sugair, Consultant, Nuclear Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, KSA |
| |
|
| 17:20 |
Q & A |
| |
|
| 17:30 |
Day 1 Adjournment |
| |
|
| Invited Speaker Faculty: |
|
Chair: Dr. Mohammad Mohamadiyeh, MD, MSc, FEBNM, Chief & Senior Consultant, Nuclear Medicine, Tawam Hospital/Johns Hopkins, Al Ain, UAE
Dr. Mohei Abu Zeid, Consultant Nuclear Medicine, Department of Radiology, King Faisal Specialist Hospital and Research Center Riyadh, KSA
Dr. Abdulaziz Al Sugair, Consultant, Nuclear Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, KSA
Dr. Maryam Aslani, MD, FRCPC, FACRO, Consultant Radiation Oncologist, Gulf International Cancer Center, Abu Dhabi, UAE
Priv.-Doz. Dr. Lutz S. Freudenbery, MA, MBA, Senior Physician, Zentrum for Radiology and Nuclear Medicine; Research Fellow, Department of Nuclear Medicine, University of Duisburg-Essen, Greven-broich, Germany
Dr. Rakesh Ganatra, Consultant Radiologist/Nuclear Medicine Physician, Queens Medical Centre, Nottingham, UK
Dr. Aly Abdel Razek, MD, FACRO, Executive Director, Gulf International Cancer Centre, Chief of Radiation Oncology, Abu Dhabi, UAE
Prof. Sobhan Vinjamuri, MD, MSc, FRCP, Consultant, Nuclear Medicine, Royal Liverpool University Hospital, UK
Dr. Richard Wahl, Director; Nuclear Medicine/PET; Vice Chair, New Technology and Business Development, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
|
|
|